Johnson & Johnson’s recent spinoff of its consumer products arm has left it as a pure-play healthcare company, supporting a reliable dividend stream. The stock yields 2.37% and pays an annual per-share dividend of $5.20, underpinned by a 48.9% payout ratio. Over the first nine months of 2025, J&J generated $14.3 billion in free cash flow and distributed $9.3 billion to shareholders, sustaining a 63-year streak of consecutive dividend increases. Investors seeking passive income can count on J&J’s diversified medical-technology and pharmaceutical portfolio to maintain cash flow even in weaker markets.

Johnson & Johnson will report fourth-quarter results before the market opens on Wednesday, January 21. Analysts expect continued growth in MedTech, where procedures such as joint reconstruction and interventional cardiology remain strong, and resilient pharma sales led by new immunology and oncology launches. In the third quarter, J&J posted $24 billion in revenue with a 69.6% gross margin, raised full-year sales guidance, and kept its operational EPS outlook intact. Investors will watch guidance for 2026 and updates on the rollout of next-generation surgical devices and key drug approvals in neuroscience and infectious disease.

Following a more than 50% rally over the past 12 months, J&J now trades above 21 times consensus forward EPS, exceeding its five-year average multiple. This valuation premium has led at least one major brokerage to downgrade the stock to Hold, citing limited upside despite strong underlying fundamentals. The stretched multiple reduces the margin of safety for new purchases, prompting investors to weigh current income benefits against modest near-term capital appreciation potential.

Looking ahead, J&J is focusing on next-generation implantable devices and targeted oncology therapies. The DePuy Synthes unit has expanded its footprint in robot-assisted surgery systems, while the pharmaceutical division is advancing several Phase III trials in immuno-oncology. Management also highlighted potential margin expansion from higher-value products and operational efficiencies realized through recent restructuring efforts. These initiatives aim to drive mid-single-digit revenue growth over the next three years and support continued dividend increases.